When Shire's new CEO Flemming Ornskov talks, analysts listen. And then some of them talk to Bloomberg . But their stories aren't always consistent.
Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Alison Bryant ( email | Twitter ) and we will feature it...
Shire CEO Angus Russell's 13-year stint at the helm has provided a classic case study on how to efficiently build a biotech company.
The Telegraph in the U.K. is reporting that the market buzz indicates that GSK is in talks with BioMarin, the rare disease drug outfit that has been snapping up programs in recent months.
When Shire ($SHPGY) bought out Advanced BioHealing in San Diego last year for $750 million, it trumpeted the addition of a new unit focused specially on regenerative medicine. And today it followed up with a blueprint to increase its footprint in that branch of biotech with a corporate campus in the Southern California biotech hub and plans to hire hundreds of new workers.
Last year the top 10 biotechs in the world spent $10.2 billion on R&D, up a whopping 13% over their $8.9 billion track record in 2010.
The active ingredient in Lialda proved no better than a placebo after two years of treatment for diverticulitis.
News that tiny FerroKin BioSciences earned a big buyout deal with Shire ($SHPGY) has helped spotlight the growing popularity of the virtual biotech model.
Fresh off a disappointing decision to jerk its marketing application for Replagal, Shire bounced right back with its announcement that it has scooped up the Bay Area biotech FerroKin BioSciences in a $325 million deal. Shire is paying $100 million upfront for FerroKin, with the rest offered in potential milestones.
GlaxoSmithKline ( $GSK ) has grabbed rights to biotech startup Angiochem's early-stage program for treating a lysosomal storage disease. The deal comes as the London-based drug giant and its large...